Non-Hodgkin Lymphoma | Specialty

Dr. Bello on Biomarkers in Follicular Lymphoma

August 31st 2018

Celeste Bello, MD, hematologist/oncologist, Moffitt Cancer Center, discusses investigational biomarkers in follicular lymphoma.

Axicabtagene Ciloleucel Approved in Europe for DLBCL, PMBCL

August 27th 2018

The European Commission has approved axicabtagene ciloleucel (axi-cel; Yescarta) as a treatment for adult patients with relapsed/refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma.

Tisagenlecleucel Approved in Europe for DLBCL, ALL

August 27th 2018

The European Commission has approved tisagenlecleucel (Kymriah) for the treatment of either adult patients with relapsed/refractory diffuse large B-cell lymphoma, or patients up to 25 years of age with relapsed B-cell acute lymphoblastic leukemia.

FDA Approves Ibrutinib/Rituximab for Waldenstrom Macroglobulinemia

August 27th 2018

The FDA has approved ibrutinib in combination with rituximab for the treatment of patients with Waldenström macroglobulinemia.

Dr. Roschewski on the Treatment of Burkitt Lymphoma in Adults

August 16th 2018

Mark J. Roschewski, MD, staff clinician, associate research clinician, clinical director, Malignancies Branch of the Center for Cancer Research, National Cancer Institute, discusses the treatment of Burkitt lymphoma in adult patients.

Flinn Highlights CAR T-Cell Developments in Lymphoma

August 9th 2018

Ian W. Flinn, MD, PhD, discusses the latest developments with CAR T-cell therapies and other recent advances in the field of lymphoma.

Dr. Bierman on Unmet Needs for Patients With CNS Involvement in Aggressive NHL

August 8th 2018

Philip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses unmet needs for patients with central nervous system (CNS) involvement in aggressive subtypes of non–Hodgkin lymphoma (NHL).

FDA Approves Mogamulizumab for CTCL

August 8th 2018

The FDA has approved mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.

Dr. Flinn on the iNNOVATE Trial in Waldenstrom Macroglobulinemia

August 8th 2018

Ian Flinn, MD, PhD, director of the Blood Cancer Research Program, Sarah Cannon Research Institute, discusses the iNNOVATE trial in Waldenstrom macroglobulinemia.

ctDNA Emerges as Promising Biomarker for Lymphoma

August 7th 2018

David M. Kurtz, MD, PhD, discusses the clinical use of circulating tumor DNA in lymphoma.

Dr. Ansell on Strategies to Address Immune Evasion in Lymphoma

August 7th 2018

Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses strategies addressing immune evasion in patients with lymphoma.

Dr. Bierman Discusses CNS Involvement in Aggressive NHL

August 3rd 2018

Philip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses central nervous system (CNS) involvement in aggressive subtypes of non-Hodgkin lymphoma.

Dr. Smith Discusses Double-Hit and Triple-Hit Lymphoma

July 31st 2018

Sonali M. Smith, MD, Elwood V. Jensen Professor in Medicine, director, Lymphoma Program, University of Chicago Medicine, discusses double-hit and triple-hit lymphoma.

Dr. Kurtz on the Clinical Utility of Cell-Free DNA in Lymphoma

July 24th 2018

David M. Kurtz, MD, PhD, instructor of medicine, Postdoctoral Fellow, Divisions of Oncology & Hematology, Stanford Cancer Center, Stanford University, discusses the utility of cell-free DNA in lymphoma.

Lenalidomide/Rituximab Improves PFS in Phase III Indolent Lymphoma Study

July 24th 2018

Combining lenalidomide with rituximab significantly improved progression-free survival compared with rituximab alone for the treatment of patients with relapsed/refractory indolent lymphoma.

Evolving Treatment Landscape of Follicular Lymphoma

July 24th 2018

Novel Therapies for the Treatment of Follicular Lymphoma

July 24th 2018

Personalized Immunotherapy in Follicular Lymphoma

July 24th 2018

R2 Regimen: RELEVANCE and AUGMENT Studies

July 24th 2018

PcP Prophylaxis in Relapsed Follicular Lymphoma

July 24th 2018